ASCO 2014 Highlights
Chicago, IL—According to a survey presented at the 2014 American Society of Clinical Oncology (ASCO) meeting, the majority of patients with cancer want to have cost-of-treatment discussions with their oncologists. And when they occur, these discussions do not lead to negative feelings in most patients.
Delaying ADT for PSA-Only Relapse May Be Viable Option for Men with Prostate Cancer and PSA-Only Relapses
Chicago, IL—Delaying androgen deprivation therapy (ADT) for at least 2 years did not lead to worse overall survival or prostate cancer–specific survival compared with the initiation of ADT within 3 months of rising prostate-specific antigen (PSA) in men with PSA-only relapse (ie, biochemical relapse) after the primary treatment of prostate cancer with surgery or radiation, according to the results of a large population-based study presented at the 2014 American Society of Clinical Oncology (ASCO) meeting and highlighted at a press briefing.
Nationwide Adoption of LDCT Screening Will Detect More Early-Stage Lung Cancer, but at Substantial Economic Cost
Chicago, IL—The US Preventive Services Task Force (USPSTF) recommends annual low-dose computed tomography (LDCT) lung cancer screening for patients at high risk. What would it mean in terms of cost to society if those recommendations were implemented in the Medicare population?
Obesity Ups Death Risk in Premenopausal Patients with ER-Positive, but Not ER-Negative, Breast Cancer
Chicago, IL—Obesity increased the risk for breast cancer–associated death in premenopausal patients with estrogen receptor (ER)-positive breast cancer, had little effect in postmenopausal women with ER-positive disease, and had no effect in patients with ER-negative disease, according to results of a large study of 80,000 women with early breast cancer that were reported at the 2014 American Society of Clinical Oncology (ASCO) meeting.
Chicago, IL—AZD9291, a novel mutation-selective tyrosine kinase inhibitor (TKI), may become a treatment option for patients with advanced, EGFR-mutated non–small-cell lung cancer (NSCLC) that has progressed with standard EGFR inhibitors, according to results of a phase 1 study presented at the 2014 American Society of Clinical Oncology (ASCO) meeting and highlighted at a press briefing.
Cetuximab versus Bevacizumab: Comparable Benefit as First-Line Therapy for Metastatic Colorectal Cancer
Chicago, IL—Although the majority of oncologists believe that discussing the costs of care with the patient is important, many report a lack of resources available to them to inform cost-benefit decisions and a lack of time to discuss these issues with patients.
Chicago, IL—The question of value in oncology continues to pose challenges for oncologists and payers alike, as the costs of therapy continue to rise and health plans are wrestling with the need to design insurance coverage that promotes value.
Results 1 - 9 of 9